CysLT1 Antagonist Q8 |
| رقم الكتالوجGB40166 |
CysLT1 antagonist Q8 inhibits developmental angiogenesis in transgenic fluorescent zebrafish, and inhibits human microvascular endothelial cell (HMEC-1) proliferation, tubule formation, and migration. CysLT1 antagonist Q8 elicits antiangiogenic effects in a VEGF-independent in vitro model of angiogenesis and exerts an additive antiangiogenic response with the anti-VEGF biologic bevacizumab.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1541762-55-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CysLT1 antagonist Q8 inhibits developmental angiogenesis in transgenic fluorescent zebrafish, and inhibits human microvascular endothelial cell (HMEC-1) proliferation, tubule formation, and migration. CysLT1 antagonist Q8 elicits antiangiogenic effects in a VEGF-independent in vitro model of angiogenesis and exerts an additive antiangiogenic response with the anti-VEGF biologic bevacizumab.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *